After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

The University of Pennsylvania, biotech firm BioNTech, and Osage University Partners, a venture capital firm in Bala Cynwyd, ...

Congressional inaction has led to the expiration of the federal government’s SBIR/STTR program, cutting off a biotechnology ...

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...

This special report details the Central Bureau of Investigation's (CBI) probe into the deadly Karur stampede, which resulted ...

A key US approval is great news for this company. The post Which biotech company's shares have rocketed to a new high on good ...

This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.

From lab space and coffee bars to jobs and long-term returns, mid-tier life sciences hubs may be better positioned than the biggest biotech boomtowns.

CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, ...

An Instagram post about the last two northern white rhinos references a scenario conservationists have warned us about for ...